Greg Durm, MD on the Current Role of Immunotherapy for NSCLC

Posted: Tuesday, May 28, 2024

Greg Durm, MD, of Indiana University, discusses the current role of immunotherapy for non–small cell lung cancer (NSCLC), which patients with advanced disease may benefit from immunotherapy beyond disease progression, and how the combination of pembrolizumab and chemotherapy can best be used.

---